Multiagent Combo Bests Immunotherapy Alone against Colorectal Cancer

Compared with atezolizumab monotherapy, a combination of chemotherapy, atezolizumab, and bevacizumab led to dramatically improved progression-free survival in patients with mismatch repair-deficient /microsatellite instability-high metastatic colorectal cancer. Because these patients often experience disease progression on immunotherapy, the results suggest that the combination approach could improve how they fare.